SEARCH:   Advanced

Blood, 1 February 2008, Vol. 111, No. 3, pp. 1039-1043. Prepublished online as a Blood First Edition Paper on October 11, 2007; DOI 10.1182/blood-2007-07-103523. This Article Full Text Full Text (PDF) Erratum (v112,p452) All Versions of this Article: blood-2007-07-103523v1 111/3/1039    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hochhaus, A. Articles by Kantarjian, H. M. Search for Related Content PubMed PubMed Citation Articles by Hochhaus, A. Articles by Kantarjian, H. M. Related Collections Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- treatment Andreas Hochhaus1, Brian Druker2, Charles Sawyers3, Francois Guilhot4, Charles A. Schiffer5, Jorge Cortes6, Dietger W. Niederwieser7, Carlo Gambacorti-Passerini8, Richard M. Stone9, John Goldman10, Thomas Fischer11, Stephen G. O'Brien12, Jose J. Reiffers13, Manisha Mone14, Tillmann Krahnke14, Moshe Talpaz15, and Hagop M. Kantarjian6 1 Medizinische Fakultaet Mannheim, University of Heidelberg, Mannheim, Germany; 2 Oregon Health and Science University Cancer Institute, Portland; 3 Memorial Sloan Kettering Cancer Center, New York, NY; 4 Centre Hospitalier Universitaire (CHU) La La Milétri, Poitiers, France; 5 Karmanos Cancer Institute, Detroit, MI; 6 Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston; 7 University of Leipzig, Leipzig, Germany; 8 S. Gerardo Hospital, University of Milano Biocca, Monza, Italy; 9 Dana-Farber Cancer Institute, Boston, MA; 10 Imperial College London, London, United Kingdom; 11 University of Mainz, Mainz, Germany; 12 University of Newcastle, Newcastle, United Kingdom; 13 Laboratoire de Greffe de Moelle, Université Victor Segalen, Bordeaux, France; 14 Novartis Pharmaceuticals, East Hanover, NJ; and 15 University of Michigan, Ann Arbor Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon- (IFN) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 months of starting imatinib; however, some patients achieved initial MCyR and CCyR more than 5 years after imatinib initiation. Estimated rates of freedom from progression to accelerated phase (AP) and blastic phase (BP) and overall survival at 6 years were 61% and 76%, respectively. Both freedom from progression to AP/BP and overall survival (OS) were associated with cytogenetic response level at 12 months. No increase in rates of serious adverse events was observed with continuous use of imatinib for up to 6.5 years, compared with earlier time points. Imatinib continues to be an effective and safe therapy for patients with CP CML after failure of IFN. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Not too late for imatinib Ruben A. Mesa Blood 2008 111: 973-974. [Full Text] [PDF] This article has been cited by other articles: D. J. Kominsky, J. Klawitter, J. L. Brown, L. G. Boros, J. V. Melo, S. G. Eckhardt, and N. J. Serkova Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells Clin. Cancer Res., May 15, 2009; 15(10): 3442 - 3450. [Abstract] [Full Text] [PDF] M. Baccarani, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv105 - iv107. [Full Text] [PDF] F. Palandri, I. Iacobucci, S. Soverini, F. Castagnetti, A. Poerio, N. Testoni, G. Alimena, M. Breccia, G. Rege-Cambrin, M. Tiribelli, et al. Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response Clin. Cancer Res., February 1, 2009; 15(3): 1059 - 1063. [Abstract] [Full Text] [PDF] S. Redaelli, R. Piazza, R. Rostagno, V. Magistroni, P. Perini, M. Marega, C. Gambacorti-Passerini, and F. Boschelli Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants J. Clin. Oncol., January 20, 2009; 27(3): 469 - 471. [Full Text] [PDF] B. J. Druker Translation of the Philadelphia chromosome into therapy for CML Blood, December 15, 2008; 112(13): 4808 - 4817. [Abstract] [Full Text] [PDF] H. Konig, M. Copland, S. Chu, R. Jove, T. L. Holyoake, and R. Bhatia Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells Cancer Res., December 1, 2008; 68(23): 9624 - 9633. [Abstract] [Full Text] [PDF] S. J. Lee, M. Kukreja, T. Wang, S. A. Giralt, J. Szer, M. Arora, A. E. Woolfrey, F. Cervantes, R. E. Champlin, R. P. Gale, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia Blood, October 15, 2008; 112(8): 3500 - 3507. [Abstract] [Full Text] [PDF] J. S. Khorashad, H. de Lavallade, J. F. Apperley, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al. Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression J. Clin. Oncol., October 10, 2008; 26(29): 4806 - 4813. [Abstract] [Full Text] [PDF] Imatinib for CML Patients in Whom Interferon Has Failed Journal Watch Oncology and Hematology, March 18, 2008; 2008(318): 1 - 1. [Full Text]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020